首页> 美国卫生研究院文献>Biochemistry and Biophysics Reports >Selective depletion of basophils ameliorates immunoglobulin E-mediated anaphylaxis
【2h】

Selective depletion of basophils ameliorates immunoglobulin E-mediated anaphylaxis

机译:嗜碱性粒细胞的选择性消耗可改善免疫球蛋白E介导的过敏反应

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Basophils, which are the rarest granulocytes, play crucial roles in protective immunity against parasites and development of allergic disorders. Although immunoglobulin (Ig)E-dependent responses via receptor for IgE (FcεRI) in basophils have been extensively studied, little is known about cell surface molecules that are selectively expressed on this cell subset to utilize the elimination in vivo through treatment with monoclonal antibody (mAb). Since CD200 receptor 3 (CD200R3) was exclusively expressed on basophils and mast cells (MCs) using a microarray screening, we have generated anti-CD200R3 mAb recognizing CD200R3A. In this study we examined the expression pattern of CD200R3A on leukocytes, and the influence of the elimination of basophils by anti-CD200R3A mAb on allergic responses. Flow cytometric analysis showed that CD200R3A was primarily expressed on basophils and MCs, but not on other leukocytes. Administration with anti-CD200R3A mAb led to the prominent specific depletion of tissue-resident and circulating basophils, but not MCs. Furthermore, in vivo depletion of basophils ameliorated IgE-mediated systemic and local anaphylaxis. Taken together, these findings suggest that CD200R3A is reliable cell surface marker for basophils in vivo, and targeting this unique molecule with mAb for the elimination of basophils may serve as a novel therapeutic strategy in ameliorating the allergic diseases.
机译:嗜碱性粒细胞是最稀有的粒细胞,在针对寄生虫的保护性免疫和过敏性疾病的发展中起着至关重要的作用。尽管已经广泛研究了嗜碱性粒细胞中通过IgE(FcεRI)受体产生的免疫球蛋白(Ig)E依赖性应答,但对于在该细胞亚群上选择性表达以利用单克隆抗体治疗体内消除作用的细胞表面分子知之甚少( mAb)。由于使用微阵列筛选,CD200受体3(CD200R3)仅在嗜碱性粒细胞和肥大细胞(MC)上表达,因此我们已经产生了识别CD200R3A的抗CD200R3 mAb。在这项研究中,我们检查了CD200R3A在白细胞上的表达模式,以及抗CD200R3A mAb消除嗜碱性粒细胞对变态反应的影响。流式细胞仪分析表明CD200R3A主要在嗜碱性粒细胞和MCs上表达,而在其他白细胞上不表达。用抗CD200R3A mAb给药可导致组织驻留和循环中的嗜碱性粒细胞显着的特异性消耗,而MC则没有。此外,嗜碱性粒细胞的体内消耗改善了IgE介导的全身和局部过敏反应。综上所述,这些发现表明CD200R3A是体内嗜碱性粒细胞的可靠细胞表面标志物,并且用mAb靶向该独特分子以消除嗜碱性粒细胞可以作为缓解过敏性疾病的新治疗策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号